Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCMA-CART±ASCT in Treating Young Multiple Myeloma Patients
NCT07169500Phase 2Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Mar 2025
- Primary completion
- Mar 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label trial of BCMA-CART in multiple myeloma (MM) (2 arms), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Minimal Residual Disease negativity rate at 3 months. Started Mar 2025; status: recruiting.
02
Drugs
BCMA-CART
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07169500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07169500.